NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Presents Data from FLEX Study at Miami Breast 2024
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
Read MoreAgendia Reports First Patient Enrolled in DEBRA Trial Using MammaPrint
MammaPrint 70-gene signature to aid in evaluation of de-escalation of radiation therapy in Stage I, Hormone Sensitive, HER2-Negative breast cancer
Read MoreAgendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan’s Dr. Erin Cobain
SWOG S2206 will use MammaPrint® breast cancer recurrence test to examine response to immunotherapy in women with high-risk HR+ breast cancer.
Read More